Cervical Cancer, Head and Neck Cancer, HPV16 Related Cancers, Non Small Cell Lung Cancer, NUT Carcinoma, Sarcoma, Uveal Melanoma
Conditions
Keywords
Loss of Heterozygosity, HLA, Carcinoma, MAGE-A1, Adenocarcinoma, Squamous Cell Carcinoma, Epithelial Carcinoma, HPV Positive Cancers, TScan Therapeutics, TSCAN-002, TSCAN-003, PRAME, MAGE-C2, MAGE-A4, Sarcoma, Human Papillomavirus, Solid Tumor, HPV Positive Anogenital Cancer
Brief summary
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.
Detailed description
This multicenter screening study will be conducted to determine a participant's tumor-associated antigen expression, HLA types and loss of HLA heterozygosity status for potential enrollment in a TScan sponsored clinical study. No treatment intervention will occur as part of this screening study. Participants will be required to provide a buccal swab to assess their HLA types and a saliva sample to assess for HLA loss of heterozygosity. For participants with an HLA type for which TScan has an open clinical study, archival tissue (less than 8 months old) will be needed to assess for tumor-associated antigen expression. If archival tissue is not available or older than 8 months, a fresh tumor biopsy will be required.
Interventions
DIAGNOSTIC_TESTTumor and HLA Profiling
HLA genotyping and tumor tissue profiling for certain tumor-associated antigens and HLA LOH.
Sponsors
TScan Therapeutics, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to provide written informed consent. * Male or female aged ≥18 years at the time of signing the informed consent. * Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study: * Head and neck cancer * Cervical cancer * Non-small cell lung cancer * HPV positive anogenital cancers * Sarcoma * Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate. * Willing to provide a buccal swab for HLA testing * Willing to provide a saliva sample to use as a normal control for the LOH assay * Have access to an adequate FFPE tumor block that is \<8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team.
Exclusion criteria
• Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of subjects with TAA expression, HLA typing and HLA loss. | 3 years | To identify participants that could potentially be eligible for the TScan Therapeutics clinical trials. |
Countries
United States
Outcome results
None listed